FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.
Pretreatment Vitamin Supplementation Folic Acid : Patients should take folic acid 1.0-1.25 mg orally once daily beginning 10 days before the first dose of FOLOTYN. Continue folic acid during the full course of therapy and for 30 days after the last dose of FOLOTYN [ see Warnings and Precautions ( 5.1 , 5.2 ) ]. Vitamin B 12 : Administer vitamin B 12 1 mg intramuscularly within 10 weeks prior to the first dose of F...
FOLOTYN is available in single-dose clear glass vials containing pralatrexate at a concentration of 20 mg/mL as a preservative-free, sterile, clear yellow solution individually packaged for intravenous use in the following presentations: NDC 48818-001-01: 20 mg of pralatrexate in 1 mL solution in a vial (20 mg / 1 mL) NDC 48818-001-02: 40 mg of pralatrexate in 2 mL solution in a vial (40 mg / 2 mL) Vials must be s...
www.FOLOTYN.com
www.fda.gov/medwatch
www.osha.gov/dts/osta/oFOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.
Pretreatment Vitamin Supplementation
Dosing and Administration
The recommended dose of FOLOTYN is 30 mg/m2 administered as an intravenous push over 3-5 minutes via the side port of a free-flowing 0.9% Sodium Chloride Injection, intravenous line once weekly for 6 weeks in 7-week cycles until progressive disease or unacceptable toxicity. The calculated dose of FOLOTYN should be aseptically withdrawn into a syringe for immediate use. Do not dilute FOLOTYN.
For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), the recommended dose of FOLOTYN is 15 mg/m2.
FOLOTYN is a clear, yellow solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use any vials exhibiting particulate matter or discoloration.
Management of severe or intolerable adverse reactions may require dose omission, reduction, or discontinuation of FOLOTYN therapy.
Monitoring
Monitor complete blood cell counts and severity of mucositis at baseline and weekly. Perform serum chemistry tests, including renal and hepatic function, prior to the start of the first and fourth dose of each cycle.
Dose Modification Recommendations
Prior to administering any dose of FOLOTYN:
Doses may be omitted or reduced based on patient tolerance. Omitted doses will not be made up at the end of the cycle; once a dose reduction occurs for toxicity, do not re-escalate. For dose modifications and omissions, use the guidelines in Tables 1, 2, and 3.
For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), the recommended starting dose of FOLOTYN is 15 mg/m2 with dose modification to 10 mg/m2 for the toxicities specified in Tables 1, 2, and 3.
| Mucositis Gradea on Day of Treatment | Action | Dose upon Recovery to ≤ Grade 1 | Dose Upon Recovery in Patients with Severe Renal Impairment |
| Grade 2 | Omit dose | Continue prior dose | Continue prior dose |
| Grade 2 recurrence | Omit dose | 20 mg/m2
| 10 mg/m2
|
| Grade 3 | Omit dose | 20 mg/m2
| 10 mg/m2
|
| Grade 4 | Stop therapy |
a Per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3.0)
| Blood Count on Day of Treatment | Duration of Toxicity | Action | Dose upon Restart | Dose Upon Recovery in Patients with Severe Renal Impairment |
| Platelet < 50,000/mcL | 1 week | Omit dose | Continue prior dose | Continue prior dose |
| 2 weeks | Omit dose | 20 mg/m2
| 10 mg/m2
| |
| 3 weeks | Stop therapy | |||
| ANC 500-1,000/mcL and no fever | 1 week | Omit dose | Continue prior dose | Continue prior dose |
| ANC 500-1,000/mcL with fever or ANC < 500/mcL | 1 week | Omit dose, give G‑CSF or GM‑CSF support | Continue prior dose with G-CSF or GM‑CSF support | Continue prior dose with G-CSF or GM‑CSF support |
| 2 weeks or recurrence | Omit dose, give G‑CSF or GM‑CSF support | 20 mg/m2 with G-CSF or GM-CSF support | 10 mg/m2 with G-CSF or GM-CSF support | |
| 3 weeks or 2nd recurrence | Stop therapy |
G-CSF=granulocyte colony-stimulating factor; GM-CSF=granulocyte macrophage colony-stimulating factor
| Toxicity Grade a on Day of Treatment | Action | Dose upon Recovery to ≤ Grade 2 | Dose Upon Recovery in Patients with Severe Renal Impairment |
| Grade 3 | Omit dose | 20 mg/m2
| 10 mg/m2
|
| Grade 4 | Stop therapy |
a Per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3.0)
FOLOTYN is a cytotoxic anticancer agent. Caution should be exercised in handling, preparing, and administering of the solution. The use of gloves and other protective clothing is recommended. If FOLOTYN comes in contact with the skin, immediately and thoroughly wash with soap and water. If FOLOTYN comes in contact with mucous membranes, flush thoroughly with water.
Several published guidelines for handling and disposal of anticancer agents are available1-4.
FOLOTYN is available as a clear yellow solution in sterile, single-dose vials containing pralatrexate at a concentration of 20 mg/mL in the following presentations:
20 mg of pralatrexate in 1 mL solution in a vial (20 mg / 1 mL)
40 mg of pralatrexate in 2 mL solution in a vial (40 mg / 2 mL)
None
FOLOTYN can cause bone marrow suppression, manifested by thrombocytopenia, neutropenia, and/or anemia. Monitor complete blood counts and omit and/or reduce the dose based on ANC and platelet count prior to each dose as outlined in Section 2.2 Table 2. Administer vitamin B12 and instruct patients to take folic acid to reduce the risk of treatment-related hematological toxicity [see Dosage and Administration (2.1, 2.2) and Adverse Reactions (6.1)].
FOLOTYN can cause mucositis. Monitor for mucositis weekly and if ≥ Grade 2 mucositis is observed, omit and/or reduce the dose as outlined in Section 2.2 Table 1. Administer vitamin B12 and instruct patients to take folic acid to reduce the risk of mucositis [see Dosage and Administration (2.1, 2.2 ) and Adverse Reactions (6.1)].
FOLOTYN can cause severe dermatologic reactions, which may result in death. These dermatologic reactions have been reported in clinical studies (14/663 patients [2.1%]) and post marketing experience, and have included skin exfoliation, ulceration, and toxic epidermal necrolysis (TEN). They may be progressive and increase in severity with further treatment, and may involve skin and subcutaneous sites of known lymphoma. Monitor patients with dermatologic reactions closely, and if severe, withhold or discontinue FOLOTYN [see Adverse Reactions (6.2) and Use in Specific Populations (8.7)].
FOLOTYN can cause tumor lysis syndrome (TLS). Monitor patients who are at increased risk of TLS and treat promptly.
FOLOTYN can cause hepatic toxicity and liver function test abnormalities. Persistent liver function test abnormalities may be indicators of hepatic toxicity and require dose modification or discontinuation. Monitor liver function tests. Omit dose until recovery, adjust or discontinue therapy based on the severity of the hepatic toxicity [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].
Patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity. Monitor patients for renal function and systemic toxicity and adjust dosing accordingly.
Serious adverse drug reactions including toxic epidermal necrolysis and mucositis were reported in patients with end stage renal disease (ESRD) undergoing dialysis who were administered FOLOTYN therapy. Avoid FOLOTYN use in patients with end stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk [see Dosage and Administration (2.2), Adverse Reactions (6.2), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)].
FOLOTYN can cause fetal harm when administered to a pregnant woman. FOLOTYN was embryotoxic and fetotoxic in rats and rabbits. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1)].
The following serious adverse reactions are described below and elsewhere in the labeling:
The most common adverse reactions observed in patients with peripheral T-cell lymphoma (PTCL) treated with FOLOTYN were mucositis, thrombocytopenia, nausea, and fatigue.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
The safety of FOLOTYN was evaluated in 111 PTCL patients in a single-arm clinical study in which patients received a starting dose of 30 mg/m2 once weekly for 6 weeks in 7-week cycles. The median duration of treatment was 70 days (range 1-540 days).
Most Frequent Adverse Reactions
Table 4 summarizes the most frequent adverse reactions, regardless of causality, using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0).
| N=111 | ||||||
| Total | Grade 3 | Grade 4 | ||||
| Preferred Term | N | % | N | % | N | % |
| Any Adverse Event | 111 | 100 | 48 | 43 | 34 | 31 |
| Mucositisa
| 78 | 70 | 19 | 17 | 4 | 4 |
| Thrombocytopeniab
| 45 | 41 | 15 | 14 | 21 | 19b
|
| Nausea | 44 | 40 | 4 | 4 | 0 | 0 |
| Fatigue | 40 | 36 | 5 | 5 | 2 | 2 |
| Anemia | 38 | 34 | 17 | 15 | 2 | 2 |
| Constipation | 37 | 33 | 0 | 0 | 0 | 0 |
| Pyrexia | 36 | 32 | 1 | 1 | 1 | 1 |
| Edema | 33 | 30 | 1 | 1 | 0 | 0 |
| Cough | 31 | 28 | 1 | 1 | 0 | 0 |
| Epistaxis | 29 | 26 | 0 | 0 | 0 | 0 |
| Vomiting | 28 | 25 | 2 | 2 | 0 | 0 |
| Neutropenia | 27 | 24 | 14 | 13 | 8 | 7 |
| Diarrhea | 23 | 21 | 2 | 2 | 0 | 0 |
| Dyspnea | 21 | 19 | 8 | 7 | 0 | 0 |
| Anorexia | 17 | 15 | 3 | 3 | 0 | 0 |
| Hypokalemia | 17 | 15 | 4 | 4 | 1 | 1 |
| Rash | 17 | 15 | 0 | 0 | 0 | 0 |
| Pruritus | 16 | 14 | 2 | 2 | 0 | 0 |
| Pharyngolaryngeal pain | 15 | 14 | 1 | 1 | 0 | 0 |
| Liver function test abnormalc
| 14 | 13 | 6 | 5 | 0 | 0 |
| Abdominal pain | 13 | 12 | 4 | 4 | 0 | 0 |
| Pain in extremity | 13 | 12 | 0 | 0 | 0 | 0 |
| Back pain | 12 | 11 | 3 | 3 | 0 | 0 |
| Leukopenia | 12 | 11 | 3 | 3 | 4 | 4 |
| Night sweats | 12 | 11 | 0 | 0 | 0 | 0 |
| Asthenia | 11 | 10 | 1 | 1 | 0 | 0 |
| Tachycardia | 11 | 10 | 0 | 0 | 0 | 0 |
| Upper respiratory tract infection | 11 | 10 | 1 | 1 | 0 | 0 |
cAlanine aminotransferase, aspartate aminotransferase, and transaminases increased
Serious Adverse Events
Forty-four percent of patients (n = 49) experienced a serious adverse event while on study or within 30 days after their last dose of FOLOTYN. The most common serious adverse events (> 3%), regardless of causality, were pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia. One death from cardiopulmonary arrest in a patient with mucositis and febrile neutropenia was reported in this trial. Deaths from mucositis, febrile neutropenia, sepsis, and pancytopenia occurred in 1.2% of patients treated on all FOLOTYN trials at doses ranging from 30 to 325 mg/m2.
Discontinuations
Twenty-three percent of patients (n = 25) discontinued treatment with FOLOTYN due to adverse reactions. The adverse reactions reported most frequently as the reason for discontinuation of treatment were mucositis (6%, n = 7) and thrombocytopenia (5%, n = 5).
Dose Modifications
The target dose of FOLOTYN was 30 mg/m2 once weekly for 6 weeks in 7-week cycles. The majority of patients (69%, n = 77) remained at the target dose for the duration of treatment. Overall, 85% of scheduled doses were administered.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Dermatologic Reactions
Toxic epidermal necrolysis, sometimes fatal, has been reported during post-marketing use of FOLOTYN. Fatal cases have been reported following the first dose of FOLOTYN, including when a reduced dose is given, and have been reported in patients with end-stage renal disease undergoing dialysis [see Warnings and Precautions (5.3), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)].
No formal clinical assessments of pharmacokinetic drug-drug interactions between FOLOTYN and other drugs have been conducted. The effect of co-administration of the uricosuric drug probenecid (an inhibitor of multiple transporter systems including the multidrug resistance-associated protein 2 (MRP2) efflux transporter) on pralatrexate pharmacokinetics was investigated in a Phase 1 clinical study. Co-administration of increasing doses of probenecid resulted in delayed clearance of pralatrexate and a commensurate increase in exposure [see Clinical Pharmacology (12.3)].
When administering FOLOTYN to patients receiving probenecid or other drugs that may affect relevant transporter systems (eg, NSAIDs), monitor patients closely for signs of systemic toxicity due to increased drug exposure.
Pregnancy Category D [see Warnings and Precautions (5.7)]
Embryo-Fetal Toxicity
FOLOTYN can cause fetal harm when administered to a pregnant woman. Pralatrexate was embryotoxic and fetotoxic in rats at IV doses of 0.06 mg/kg/day (0.36 mg/m2/day or about 1.2% of the clinical dose on a mg/m2 basis) given on gestation days 7 through 20. Treatment with pralatrexate caused a dose-dependent decrease in fetal viability manifested as an increase in late, early, and total resorptions. There was also a dose-dependent increase in post-implantation loss. In rabbits, IV doses of 0.03 mg/kg/day (0.36 mg/m2/day) or greater given on gestation days 8 through 21 also caused abortion and fetal lethality. This toxicity manifested as early and total resorptions, post-implantation loss, and a decrease in the total number of live fetuses. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
It is not known whether pralatrexate is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from this drug, a decision should be made whether to discontinue nursing or to discontinue FOLOTYN, taking into account the importance of FOLOTYN to the mother.
Pediatric patients were not included in clinical studies with FOLOTYN. The safety and effectiveness of FOLOTYN in pediatric patients have not been established.
In the PTCL efficacy study, 36% of patients (n = 40) were 65 years of age and over. No overall differences in efficacy and safety were observed in patients based on age (< 65 years compared with ≥ 65 years). Due to the contribution of renal excretion to overall clearance of pralatrexate (approximately 34%), age-related decline in renal function may lead to a reduction in clearance and a commensurate increase in plasma exposure. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Since elderly patients may be at higher risk, monitor more closely. Omit dose and subsequently adjust or discontinue therapy for exposure related toxicity [see Dosage and Administration (2.2), Warnings and Precautions (5.5, 5.6), Use in Specific Populations (8.6, 8.7), and Clinical Pharmacology (12.3)].
The safety, efficacy and pharmacokinetics of FOLOTYN have not been evaluated in patients with hepatic impairment. Patients with the following laboratory values were excluded from the pralatrexate lymphoma clinical trials: total bilirubin > 1.5 mg/dL; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN); and AST or ALT > 5 × ULN if documented hepatic involvement with lymphoma. Treatment with FOLOTYN can cause hepatic toxicity and liver function test abnormalities [see Dosage and Administration (2.2) and Warnings and Precautions (5.6)].
For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), the recommended dose of FOLOTYN is 15 mg/m2. For patients with mild to moderate renal impairment, dose reduction is not necessary.
Serious adverse drug reactions, including TEN and mucositis have been reported in patients with ESRD undergoing dialysis. Monitor patients for renal function and for systemic toxicity due to increased drug exposure and adjust dosing accordingly. Avoid the use of FOLOTYN in patients with end stage renal disease undergoing dialysis unless the potential benefit justifies the potential risk [see Dosage and Administration (2.1, 2.2), Warnings and Precautions (5.3, 5.6), Adverse Reactions (6.2), and Clinical Pharmacology (12.3)].
No specific information is available on the treatment of overdosage of FOLOTYN. If an overdose occurs, general supportive measures should be instituted as deemed necessary by the treating physician. Based on FOLOTYN's mechanism of action, consider the prompt administration of leucovorin.
FOLOTYN (pralatrexate injection) contains pralatrexate, which is an antineoplastic folate analog. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid. The structural formula is as follows:
Pralatrexate is a 1:1 racemic mixture of S- and R- diastereomers at the C10 position (indicated with *).
The molecular formula is C23H23N7O5 and the molecular weight is 477.48 g/mol.
Pralatrexate is an off-white to yellow solid. It is soluble in aqueous solutions at pH 6.5 or higher. Pralatrexate is practically insoluble in chloroform and ethanol. The pKa values are 3.25, 4.76, and 6.17.
FOLOTYN is supplied as a preservative-free, sterile, isotonic, non-pyrogenic clear yellow aqueous parenteral solution contained in a single-dose clear glass vial (Type I) for intravenous administration. Each 1 mL of solution contains 20 mg of pralatrexate, sufficient sodium chloride to achieve an isotonic (280-300 mOsm) solution, and sufficient sodium hydroxide, and hydrochloric acid if needed, to adjust and maintain the pH at 7.5-8.5. FOLOTYN is supplied as either 20 mg (1 mL) or 40 mg (2 mL) single-dose vials at a concentration of 20 mg/mL.
Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer.
Absorption
The pharmacokinetics of pralatrexate administered as a single agent at a dose of 30 mg/m2 administered as an intravenous push over 3-5 minutes once weekly for 6 weeks in 7-week cycles have been evaluated in 10 patients with PTCL. The total systemic clearance of pralatrexate diastereomers was 417 mL/min (S-diastereomer) and 191 mL/min (R-diastereomer). The terminal elimination half-life of pralatrexate was 12-18 hours (coefficient of variance [CV] = 62-120%). Pralatrexate total systemic exposure (AUC) and maximum plasma concentration (Cmax) increased proportionally with dose (dose range 30-325 mg/m2, including pharmacokinetics data from high-dose solid tumor clinical studies). The pharmacokinetics of pralatrexate did not change significantly over multiple treatment cycles, and no accumulation of pralatrexate was observed.
Distribution
Pralatrexate diastereomers showed a steady-state volume of distribution of 105 L (S-diastereomer) and 37 L (R-diastereomer). In vitro studies indicate that pralatrexate is approximately 67% bound to plasma proteins.
Elimination
Metabolism
In vitro studies using human hepatocytes, liver microsomes and S9 fractions, and recombinant human CYP450 isozymes showed that pralatrexate is not significantly metabolized by the phase I hepatic CYP450 isozymes or phase II hepatic glucuronidases.
Excretion
The mean fraction of unchanged pralatrexate diastereomers excreted in urine following a pralatrexate dose of 30 mg/m2 administered as an intravenous push over 3‑5 minutes was 31% (S‑diastereomer) (CV = 47%) and 38% (R-diastereomer) (CV = 45%), respectively. In a mass balance study conducted in patients with advanced cancer, an average of 39% (CV = 28%) of the administered radiolabeled pralatrexate dose was excreted in urine as parent, racemic pralatrexate (fe). An average of 34% (CV = 88%) of the administered dose was recovered in feces as total radiation (fe TR) which included both parent pralatrexate and/or any metabolites. An average of 10% (CV = 95%) of total dose was exhaled as total radioactivity over 24 hours.
Pharmacokinetics in Specific Populations
Renal Impairment
In patients with cancer without renal impairment, approximately 34% of pralatrexate was excreted unchanged into urine following a single dose of 30 mg/m2 administered as an intravenous push over 3-5 minutes. The pharmacokinetics of FOLOTYN was studied in patients with varying degrees of renal impairment. In patients with severe renal impairment (eGFR 15 to <30 mL/min/1.73 m2), the FOLOTYN dose was 15 mg/m2. Patients with normal renal clearance, mild renal impairment, and moderate renal impairment were all dosed with 30 mg/m2. Mean exposures of the pralatrexate S-diastereomer and R-diastereomer were comparable across cohorts. The mean fraction of the administered dose excreted as unchanged diastereomers in urine (fe) decreased with declining renal function. The non-renal clearance and volume of distribution of pralatrexate were unaffected by renal impairment [see Use in Specific Populations (8.7)].
Hepatic Impairment
Pralatrexate has not been studied in patients with hepatic impairment.
Gender
There was no significant effect of gender on pharmacokinetics.
Drug Interactions
In vitro studies indicated that pralatrexate does not induce or inhibit the activity of CYP450 isozymes at concentrations of pralatrexate that can be reasonably expected clinically.
In vitro, pralatrexate is a substrate for the breast cancer resistance protein (BCRP), MRP2, multidrug resistance-associated protein 3 (MRP3), and organic anion transport protein 1B3 (OATP1B3) transporter systems at concentrations of pralatrexate that can be reasonably expected clinically. Pralatrexate is not a substrate of the P glycoprotein (P-gp), organic anion transport protein 1B1 (OATP1B1), organic cation transporter 2 (OCT2), organic anion transporter 1 (OAT1), and organic anion transporter 3 (OAT3) transporter systems.
In vitro, pralatrexate inhibits MRP2 and MRP3 transporter systems ([I]/IC50 > 0.1) at concentrations of pralatrexate that can be reasonably expected clinically. MRP3 is a transporter that may affect the transport of etoposide and teniposide.
In vitro, pralatrexate did not significantly inhibit the P-gp, BCRP, OCT2, OAT1, OAT3, OATP1B1, and OATP1B3 transporter systems at concentrations of pralatrexate that can be reasonably expected clinically.
Carcinogenesis
Carcinogenicity studies have not been performed with pralatrexate.
Mutagenesis
Pralatrexate did not cause mutations in the Ames test or the Chinese hamster ovary cell chromosome aberration assay. Nevertheless, these tests do not reliably predict genotoxicity for this class of compounds. Pralatrexate did not cause mutations in the mouse micronucleus assay.
Impairment of Fertility
No fertility studies have been performed.
Peripheral T-cell Lymphoma (PTCL)
The safety and efficacy of FOLOTYN was evaluated in an open-label, single-arm, multi-center, international trial that enrolled 115 patients with relapsed or refractory PTCL. One hundred and eleven patients were treated with FOLOTYN at 30 mg/m2 once weekly by IV push over 3-5 minutes for 6 weeks in 7-week cycles until disease progression or unacceptable toxicity. Of the 111 patients treated, 109 patients were evaluable for efficacy. Evaluable patients had histologically confirmed PTCL by independent central review using the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification, and relapsed or refractory disease after at least one prior treatment.
The primary efficacy endpoint was overall response rate (complete response, complete response unconfirmed, and partial response) as assessed by International Workshop Criteria (IWC). The key secondary efficacy endpoint was duration of response. Response assessments were scheduled at the end of cycle 1 and then every other cycle (every 14 weeks). Duration of response was measured from the first day of documented response to disease progression or death. Response and disease progression were evaluated by independent central review using the IWC.
The median age of treated patients was 59.0 years (range 21-85); 68% were male and 32% were female. Most patients were White (72%) and other racial origins included: Black (13%), Hispanic (8%), Asian (5%), other and unknown (<1% each). Patients had an Eastern Cooperative Oncology Group (ECOG) performance status at study entry of 0 (39%), 1 (44%), or 2 (17%). The median time from initial diagnosis to study entry was 15.6 months (range 0.8 – 322.3).
The median number of prior systemic therapies was 3 (range 1-12). Approximately one-fourth of patients (24%, n = 27) did not have evidence of response to any previous therapy. Approximately two-thirds of patients (63%, n = 70) did not have evidence of response to their most recent prior therapy before entering the study.
In all evaluable patients (n = 109) treated with FOLOTYN, the response rate, as determined by independent central review by IWC, was 27% (n = 29) (Table 5).
| Evaluable Patients (N=109) | ||||
| N (%) | 95% CI | Median Duration of Response | Range of Duration of Response | |
| Overall Response | ||||
| CR+CRu+PR | 29 (27) | 19, 36 | 287 days (9.4 months) | 1-503 days |
| CR/CRu | 9 (8) | |||
| PR | 20 (18) | |||
| Responses ≥ 14 weeks | ||||
| CR+CRu+PR | 13 (12) | 7, 20 | Not Reached | 98-503 days |
| CR/CRu | 7 (6) | |||
| PR | 6 (6) | |||
CR = Complete Response, CRu = Complete Response unconfirmed, PR = Partial Response
The initial response assessment was scheduled at the end of cycle 1. Of the responders, 66% responded within cycle 1. The median time to first response was 45 days (range 37-349 days).
www.osha.gov/dts/osta/o tm/otm_vi/otm_vi_2.html FOLOTYN is available in single-dose clear glass vials containing pralatrexate at a concentration of 20 mg/mL as a preservative-free, sterile, clear yellow solution individually packaged for intravenous use in the following presentations:
NDC 48818-001-01: 20 mg of pralatrexate in 1 mL solution in a vial (20 mg / 1 mL)
NDC 48818-001-02: 40 mg of pralatrexate in 2 mL solution in a vial (40 mg / 2 mL)
Vials must be stored refrigerated at 2-8°C (36-46°F) (see USP Controlled Cold Temperature) in original carton to protect from light.
Handle and dispose of FOLOTYN according to guidelines issued for cytotoxic drugs, including the use of gloves and other protective clothing to prevent skin contact [see References (15)].
Each vial of FOLOTYN is intended for single use only. Any unused drug remaining after injection must be discarded.
See FDA-approved labeling (Patient Information).
Patients should be instructed to read the Patient Information carefully.
Advise patients treated with FOLOTYN to take folic acid and vitamin B12 as a prophylactic measure to reduce the risk of possible side effects [see Dosage and Administration (2.1)].
Inform patients of the risk of low blood cell counts and to immediately contact their physician should any signs of infection develop, including fever. Inform patients to contact their physician if bleeding or symptoms of anemia occur.
Inform patients of the signs and symptoms of mucositis. Instruct patients on ways to reduce the risk of its development, and on ways to maintain nutrition and control discomfort from mucositis if it occurs.
Advise patients about the risks for and the signs and symptoms of dermatologic reactions. Instruct patients to immediately notify their physician if any skin reactions occur [see Warnings and Precautions (5.3)].
Inform patients about the risk of and the signs and symptoms of tumor lysis syndrome. Patients should be instructed to notify their physician if they experience these symptoms [see Warnings and Precautions (5.4)].
Patients should be instructed to inform their physician if they are taking any concomitant medications including prescription drugs (such as trimethoprim/sulfamethoxazole) and nonprescription drugs (such as nonsteroidal anti-inflammatory drugs) [see Drug Interactions (7)].
Patients should be instructed to tell their physician if they are pregnant or plan to become pregnant due to the risk of fetal harm. Patients should be instructed to tell their physician if they are nursing.
Manufactured for:
Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiary Allos Therapeutics, Inc.
Westminster, CO 80021
1-888-ALLOS88 (1-888-255-6788)
FOLOTYN, ALLOS, and the mobius triangle symbol are all registered trademarks of Allos Therapeutics, Inc.
U.S. Patents: 6,028,071, 7,622,470 and 8,299,078
Rev. November 2016
© 2016 Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiary Allos Therapeutics, Inc. All rights reserved.
Patient Information
FOLOTYN®(FOH-loh-tin)
(pralatrexate injection)
Read the Patient Information that comes with FOLOTYN before you start treatment and each time you get treated with FOLOTYN. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment. Talk to your doctor if you have any questions about FOLOTYN.
What is FOLOTYN?
FOLOTYN is a prescription anti-cancer (chemotherapy) medicine. FOLOTYN is used to treat people with a type of cancer called Peripheral T-cell Lymphoma (PTCL) that does not go away, gets worse, or comes back after use of another cancer treatment.
What should I tell my doctor before receiving FOLOTYN?
Before you receive FOLOTYN, tell your doctor if you:
Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how FOLOTYN works, and FOLOTYN may affect how other medicines work. Especially tell your doctor if you take:
Ask your doctor or pharmacist if you are not sure if your medicine is listed above.
Know the medicines you take. Keep a list of them and show it to your doctor or pharmacist each time you start a new medicine.
How will I receive FOLOTYN?
To lower your chances of harmful side effects, it is important that you take folic acid and vitamin B12 during your treatment with FOLOTYN. Your doctor will give you specific instructions for vitamin supplementation.
You should have regular blood tests before and during your treatment with FOLOTYN. Your doctor may change your dose of FOLOTYN or delay treatment based on the results of your blood tests and on your general condition.
What are the possible side effects of FOLOTYN?
FOLOTYN may cause serious side effects, including:
|
|
Common side effects of FOLOTYN include:
|
|
Tell your doctor about any side effect that bothers you or that does not go away.
These are not all the possible side effects of FOLOTYN. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You can report side effects to FDA at 1-800-FDA-1088.
General information about FOLOTYN
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. This patient information leaflet summarizes the most important information about FOLOTYN. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about FOLOTYN that is written for health professionals.
For more information, go to www.FOLOTYN.com or call 1-888-255-6788.
What are the ingredients in FOLOTYN?
Active ingredient: pralatrexate
Inactive ingredients: sodium chloride, sodium hydroxide, and hydrochloric acid
What is PTCL?
PTCL is a rare type of non-Hodgkin's lymphoma, a cancer of the lymphatic system. It happens when a type of T-cell (a kind of white blood cell) grows too much. PTCL may be found in different parts of the body, such as the lymph nodes, skin, bone marrow, liver, or spleen.
Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiary Allos Therapeutics, Inc.
Westminster, CO 80021
Issued: May 2010
Revised: November 2016
FOLOTYN, ALLOS, the mobius triangle symbol, and the flower symbol are all registered trademarks of Allos Therapeutics, Inc.
© 2016 Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiary Allos Therapeutics, Inc. All rights reserved.
PACKAGE CARTON - FOLOTYN 20 mg/1 mL Vial
NDC 48818-001-01
FOLOTYN®
(pralatrexate injection)
20 mg/mL
For intravenous use
Rx only
1 mL
PACKAGE CARTON - FOLOTYN 40 mg/2 mL Vial
NDC 48818-001-02
FOLOTYN®
(pralatrexate injection)
40 mg/2 mL
(20 mg/mL)
For intravenous use
Rx only
2 mL
VIAL – FOLOTYN 20 mg/1 ml
NDC 48818-001-01
FOLOTYN®
(pralatrexate injection)
20 mg/mL
Rx only
1 mL
VIAL – FOLOTYN 40 mg/2 ml
NDC 48818-001-02
FOLOTYN®
(pralatrexate injection)
40 mg/2 mL
(20 mg/mL)
Rx only
2 mL
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 48818-001-01 | ML - Milliliter | 48818-001 | b1d0dd02-ec6b-47f7-acdb-42e56d067a7b | 1 | 2012-07-24 |
| 48818-001-02 | ML - Milliliter | 48818-001 | c8636418-6888-4641-b710-4b50c3fa231f | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| pralatrexate | ACTIVE INGREDIENT | A8Q8I19Q20 | 17 | |
| pralatrexate | ACTIVE MOIETY | A8Q8I19Q20 | 17 | |
| hydrochloric acid | INACTIVE INGREDIENT | QTT17582CB | 17 | |
| sodium chloride | INACTIVE INGREDIENT | 451W47IQ8X | 17 | |
| sodium hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 17 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 17 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 48818-001 | 48818-001-01, 48818-001-02 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| PRALATREXATE | A8Q8I19Q20 | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INHALANT / RESPIRATORY (INHALATION) | 3 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SYRUP / ORAL | 2.03 mg/1ml | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / ORAL | 223 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.18 %w/v | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / TOPICAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SPRAY, METERED / NASAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 7.01 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 24 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | EMULSION / OPHTHALMIC | 0.02 %w/v | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION / OPHTHALMIC | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, EMULSION / INTRAVENOUS | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / TOPICAL | 0.23 %w/v | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SPRAY / NASAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / ORAL | 400 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | DROPS / NASAL | 10 ml | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRASPINAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / URETERAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INFILTRATION | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE / ORAL | 6 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / EPIDURAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRA-ARTICULAR | 26 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, EMULSION / INTRAVENOUS | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / SUBMUCOSAL | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAMUSCULAR | 0.86 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.68 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAVASCULAR | NA | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SWAB / TOPICAL | 0.01 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | FILM, SOLUBLE / BUCCAL | 5 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBMUCOSAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / RECTAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRATUMOR | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRABURSAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 78.36 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SUSPENSION / SOFT TISSUE | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVASCULAR | 0.86 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1800 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION, EXTENDED RELEASE / INTRA-ARTICULAR | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | LIQUID / INTRAMUSCULAR | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBMUCOSAL | 16 %w/v | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | POWDER / RESPIRATORY (INHALATION) | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVENOUS | 28773 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / AURICULAR (OTIC) | 0.9 %w/v | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / SUBCUTANEOUS | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | EMULSION / TOPICAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | EMULSION / TOPICAL | 0.2 %w/w | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | CREAM, AUGMENTED / TOPICAL | 6 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / NASAL | 7.4 mg/1ml | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRA-ARTERIAL | 840 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRABURSAL | 9 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / URETHRAL | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE, EXTENDED RELEASE / ORAL | 41 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / URETHRAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / ORAL | 2 mg/5ml |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N022468-001 | FOLOTYN | PRALATREXATE | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD | 2009-09-24 |
| N022468-002 | FOLOTYN | PRALATREXATE | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD, RS | 2009-09-24 |
| Application-product | TE code |
|---|---|
| N022468-001 | AP |
| N022468-002 | AP |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD | 2009-09-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD, RS | 2009-09-24 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD | 2009-09-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD, RS | 2009-09-24 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD | 2009-09-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD, RS | 2009-09-24 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD | 2009-09-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD, RS | 2009-09-24 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD | 2009-09-24 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD, RS | 2009-09-24 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD | 2009-09-24 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | AP | RLD, RS | 2009-09-24 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022468-001 | FOLOTYN | 20MG/ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2009-09-24 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022468-002 | FOLOTYN | 40MG/2ML (20MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2009-09-24 | 74a2ff9319b5… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N022468-001 | AP | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N022468-002 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N022468-001 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N022468-002 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N022468-001 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N022468-002 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022468-001 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022468-002 | AP | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N022468-001 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N022468-002 | AP | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022468-001 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022468-002 | AP | 1 | fd3edfee7708… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N022468-001 | AP | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N022468-002 | AP | 1 | a50c72e98297… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N022468-001 | 7622470 | 2025-05-31 | U-1015 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N022468-001 | 8299078 | 2025-05-31 | U-1004 | 2012-12-19 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N022468-002 | 7622470 | 2025-05-31 | U-1015 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N022468-002 | 8299078 | 2025-05-31 | U-1004 | 79d66fd596c7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| c815c707-88c6-4834-9279-96251cf1bf66 | 5e4cf15b-bf7b-4b83-863e-e9ef27741a51 | 2024-03-22 | Warnings, Adverse reactions | 5e4cf15b-bf7b-4b83-863e-e9ef27741a51 |
Adverse event summaries are temporarily unavailable. Other product information remains available.